BPC-157
BPC-157 is a 15-amino-acid research peptide. Selected animal injury studies and a two-person human safety pilot explore different questions; neither establishes treatment benefit for injured patients.
Research topics
Read the studies →
EXPLORE THE BIOLOGY
Content updated · how dates work
Intestinal function, absorption, and bowel conditions.
This topic groups related research questions. Shared biology does not make different peptides interchangeable, or establish a clinical benefit. Compare each paper’s population, preparation, and measured outcome.
Each peptide is sorted by the strongest kind of human study among its profile’s selected studies, and the row shows what that study found and who was studied. A higher tier means stronger evidence exists, not that the peptide works for gut & digestion: the best trial may be small, negative or about a different condition. No doses.
| Peptide | Strongest human evidence in our sources | FDA | Human safety data |
|---|---|---|---|
| FDA-approved medicine (5)Approved for the specific uses on its label, which may not be this goal. | |||
| Lanreotide | CLARINET (2014) · Human randomized trial Estimated progression-free survival at 24 months was 65.1% versus 33.0%; hazard ratio for progression or death 0.47. Overall survival and quality of life were not significantly different. The hazard ratio’s 95% CI was 0.30–0.73. Treatment-related diarrhea occurred in 26% versus 9%. Limitation: The tumor subtype and receptor status are essential. Slowing progression is not the same as curing cancer, and cannot be generalized to unrelated tumors. Studied: 204 patients with advanced, well/moderately differentiated, nonfunctioning, somatostatin-receptor-positive neuroendocrine tumors. Tumors… | FDA-approved | FDA label |
| Linaclotide | Chronic constipation trials (2011) · Human randomized trial The sustained complete-spontaneous-bowel-movement endpoint was met by roughly 16–21% of treated participants versus 3–6% with placebo across trials. Limitation: A responder had both sufficient bowel frequency and improvement from baseline over most study weeks. This is a defined constipation endpoint, not evidence of general intestinal “repair.” Studied: 1,276 patients across two trials. | FDA-approved | FDA label |
| Octreotide | PROMID (2009) · Human randomized trial Median time to tumor progression was 14.3 versus 6 months, with a hazard ratio of 0.34. Limitation: Too few deaths had occurred for a confirmatory survival conclusion. Tumor-growth control and relief of hormone-related symptoms are distinct outcomes; tumor subtype remains central. Studied: 85 patients with metastatic, well-differentiated midgut neuroendocrine tumors. | FDA-approved | FDA label |
| Plecanatide | Phase 3 constipation study (2017) · Human randomized trial Durable complete-spontaneous-bowel-movement response occurred in 21.0% and 19.5% versus 10.2% with placebo. Diarrhea occurred in about 6% versus 1.3%. Limitation: A higher response rate does not mean everyone responds. This adult constipation trial does not remove pediatric restrictions or apply to bowel obstruction. Studied: 1,394 people with chronic idiopathic constipation. | FDA-approved | FDA label |
| Teduglutide | STEPS (2012) · Human randomized trial A reduction of more than 20% in support volume at weeks 20 and 24 occurred in 63% versus 30%. Mean weekly volume reduction was 4.4 versus 2.3 liters. Limitation: A response did not necessarily mean complete independence from IV support. The outcome is specific to intestinal failure, not general gut symptoms or appetite control. Studied: 86 patients with short bowel syndrome and intestinal failure requiring parenteral support. | FDA-approved | FDA label |
| Randomized human trials (3)At least one randomized or placebo-controlled trial, which may be small, negative or about another condition. | |||
| Larazotide | Larazotide celiac-disease phase 2 trial (2015) · Human randomized trial One active-treatment group met the primary symptom endpoint; the other two did not show improvement on that endpoint. Safety was comparable with placebo during the trial. Limitation: A nonuniform response across groups makes simple dose-response claims inappropriate. Symptom scores are different from demonstrating prevention of long-term complications. Studied: 342 adults with celiac disease and persistent symptoms after at least 12 months on a gluten-free diet. | Not approved | Trials only |
| Peptide YY | PYY3-36 with and without GLP-1 (2014) · Human randomized crossover study Neither individual infusion significantly reduced food intake in this experiment. The combination reduced intake by 30.4%; nausea increased slightly. Limitation: An acute combined-hormone effect cannot be transferred to PYY alone or interpreted as sustained weight loss. Studied: 25 overweight healthy men. | Not approved | Trials only |
| VIP | TESICO aviptadil trial (2023) · Human randomized trial The primary outcome was not significantly better with aviptadil: odds ratio 1.11, 95% CI 0.80–1.55, P=0.54. Mortality was also not significantly different. Limitation: This negative comparison should remain visible. It neither proves benefit nor answers every proposed chronic use of VIP. Studied: 461 people with COVID-19-associated respiratory failure. | Not approved | Trials only |
| Small or uncontrolled human studies (1)Human reports without randomization, such as pilots, case series or open-label studies. | |||
| BPC-157 | BPC-157 · knee-pain chart review (2021) · Retrospective human chart review The authors reported that 14 of 16 patients (87.5%) described significant knee-pain relief, including 11 of 12 who received BPC-157 alone. Limitation: The knee problems varied, follow-up was inconsistent, and no imaging or function measures were used. The study did not systematically record side effects, so it says little about safety. Controlled trials would be needed to support a benefit. Studied: 16 patients at one U.S. primary-care hormone clinic, reached by phone 6–12 months after a knee injection; 12 received BPC-157 alone and 4… | Not approved | Very limited |
| Animal and lab studies only (2)No human study in our sources. | |||
| IGF-1 LR3 | See the profile for the animal and lab research. | Not approved | None |
| KPV | See the profile for the animal and lab research. | Not approved | None |
Selected studies, not a systematic review. Approval belongs to a specific product and use. Side-by-side comparisons: BPC-157 vs TB-500 (all comparisons).
BPC-157 is a 15-amino-acid research peptide. Selected animal injury studies and a two-person human safety pilot explore different questions; neither establishes treatment benefit for injured patients.
Research topics
Read the studies →IGF-1 LR3 is a modified IGF-1 analogue. A rat experiment assessed intestinal tissue growth and glucose-analogue absorption, rather than bodybuilding outcomes.
Research topics
Read the studies →KPV is a three-amino-acid peptide investigated in intestinal and immune-cell research. Its short sequence does not make clinical efficacy self-evident.
Research topics
Read the studies →Lanreotide is a prescription somatostatin analogue used in specific endocrine and neuroendocrine conditions. Its evidence depends on the disease being treated.
Prescription medicines
Read the studies →Larazotide is an investigational peptide studied for persistent symptoms in celiac disease. The featured trial kept participants on a gluten-free diet.
Research topics
Read the studies →Linaclotide is an orally administered peptide medicine for defined constipation conditions. Its clinical outcomes concern bowel function and associated symptoms.
Prescription medicines
Read the studies →Octreotide is a somatostatin-related medicine used in specialist endocrine and gastrointestinal care. Immediate- and long-acting preparations have different roles.
Prescription medicines
Read the studies →Peptide YY is a gut-hormone family involved in feeding regulation. The selected trial studied PYY3-36 alone and with GLP-1; the combined result should not be described as a proven PYY-alone effect.
Research topics
Read the studies →Plecanatide is an oral peptide medicine used for chronic idiopathic constipation and IBS with constipation in adults.
Prescription medicines
Read the studies →Teduglutide is a peptide medicine for short bowel syndrome with dependence on intravenous nutrition or fluids. It acts in a different pathway from GLP-1 medicines.
Prescription medicines
Read the studies →Vasoactive intestinal peptide participates in vascular and immune signaling. A large trial of intravenous aviptadil in COVID-19 respiratory failure did not show a significant improvement in its primary outcome.
Research topics
Read the studies →See something wrong on this page? Report a mistake · Corrections